Last reviewed · How we verify
NCT04515550
Mitochondrial Biomarkers in Huntington's Disease
trial testing lumbar puncture in Huntington Disease in 27 participants. Completed in 28 February 2022.
28 February 2022
Quick facts
| Lead sponsor | University Hospitals Cleveland Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 4 April 2019 |
| Primary completion | 28 February 2022 |
| Estimated completion | 28 February 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- lumbar puncture — full drug profile →
Conditions studied
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
University Hospitals Cleveland Medical Center
Who can join
Adults 20 to 85, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04515550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of lumbar puncture
Trials testing the same drug.
- NCT06917924 — A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS · recruiting
- NCT04024020 — Chronic Insomnia and CSF Markers of Dementia · completed
- NCT06629168 — The Usage of Telemetric Prechamber Sensor Reservoir in Management of Normal Pressure Hydrocephalus. Comparisson of Benef · completed
- NCT03217396 — Biomarkers of Synaptic Damage in Multiple Sclerosis · recruiting
- NCT01387594 — Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Fai · Phase 1 · completed
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
- NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
- NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
- NCT06774443 — Hinting Task for Huntington's Disease · recruiting
- NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
- NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting
Other University Hospitals Cleveland Medical Center trials
Trials by the same sponsor.
- NCT06997198 — Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · Phase 4 · not yet recruiting
- NCT07379814 — Rectus Abdominis Detrusor Myoplasty for Urinary Retention · not yet recruiting
- NCT07499648 — Baby Steps to Care · NA · not yet recruiting
- NCT07497737 — OMT for Adhesive Capsulitis · Phase 4 · not yet recruiting
- NCT06523166 — Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04515550 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Cleveland Medical Center
- Last refreshed: 12 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04515550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing